Genentech signs $105M upfront deal with Orionis Biosciences to develop molecular glue cancer drugs, with potential milestones ...

Roivant has its own TYK2/JAK1 inhibitor in development in the form of brepocitinib, which the biopharma licensed from Pfizer ...

Find out if gene therapy has also find its way into skin diseases. With two approvals in the last 2 years, is it the start of ...

The new tool, which assesses the DNA from a sample taken from the tumour, can achieve this in around two hours, experts found ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary, Lemonaid ...

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

Schrödinger is laying off 60 staffers, or about 7% of its workforce, in an effort to save cash and boost efficiency. | ...

Viking Therapeutics offers leaner operations, lower complexity, faster trial execution, and less execution risk. Learn more ...

Biotech firm Synthego files for bankruptcy despite a purchase agreement with Perceptive Advisors and plans for operational ...

Following President Trump's Most Favored Nation executive order, HHS and CMS have released the target price for pharmaceutical manufacturers to meet.

In the Phase 2 study of patients with chronic kidney disease, the highest dose of the drug lowered by 86% the levels of ...